Adjuvant treatment challenges in early HR+/HER2− breast cancer: the emerging role of next-generation oral SERDs
Leading breast cancer experts Dr. Sibylle Loibl and Dr. Rupert Bartsch discuss one of the most important topics in early breast cancer management today: the challenges of adjuvant treatment in patients with HR-positive, HER2-negative disease and the emerging role of next-generation oral selective estrogen receptor degraders (SERDs).
